The FDA has expanded the label of Regeneron’s blockbuster eye therapy Eylea (aflibercept), allowing the administration of a higher 8-mg dose at up to 16-week intervals, the company announced Friday.
The combination of Roche’s Tecentriq (atezolizumab) and Exelixis’ Cabometyx (cabozantinib) met one of the primary endpoints in the pivotal Phase III CONTACT-02 trial, significantly improving progression-free survival in patients with metastatic castration-resistant prostate cancer, according to interim data released Monday by the companies.
ReutersGilead Sciences said on Monday the U.S. health regulator placed a clinical hold on studies of its blood cancer drug, just a month after the company scrapped a late-stage trial due to efficacy concerns.
The company said the drug showed up to 19% weight loss after 46 weeks in a mid-stage trial.
Yesterday the company announced positive results from two early-stage clinical trials for its first in-class small molecule imipridone, a potential treatment for an incurable and aggressive type of pediatric brain tumor which demonstrated longer survival in this subset of patients.
Today the company announced that its breast cancer therapy in combination with Roche’s Kadcyla helped extend the time patients lived without their disease progressing in a late-stage trial.
A scientist at Harvard used Google’s cloud platform to clone a supercomputer for a heart disease study, in a novel move that other researchers could follow to get around a shortage of powerful computing resources and speed up their work.
The companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacle platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases.
The company was development a treatment for idiopathic pulmonary fibrosis, a condition in which the lungs become scarred and breathing becomes difficult.
The company announced Monday with its second-quarter earnings that the regulator has officially halted the Phase I study after a child with acute myeloid leukemia died following treatment.
